AMRA-MEDICAL
AMRA Medical, a leading force in the development of MRI-based body composition analyses and biomarkers, is pleased to announce their EU Medical Device Regulation (MDR) certificate for the cutting-edge AMRA® Profiler 4 body composition analysis device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829196647/en/
AMRA® Profiler 4 provides rapid and precise body composition measurements in relation to normative data, contextualizing insights at the individual patient level, with high accuracy. (Graphic: Business Wire)
The 2017/745 (EU) MDR outlines the European regulations for medical devices and contains requirements, e.g., on the production, distribution, evaluation, and surveillance of medical devices. Manufacturers of medical devices must ensure compliance to MDR prior to bringing a medical device to the EU market. These requirements ensure that a medical device placed on the European market is both safe and effective for use by patients and providers.
The certificate comes as a successor to AMRA® Profiler 4’s 510(k) clearance by the US Food and Drug Administration (FDA), comfortably meeting the high standards for both EU and US markets in the push for increased use of AMRA’s cutting-edge body composition analysis methodologies in the clinic. Now that AMRA® Profiler 4 is CE marked, the device’s conformity with European MDR General Safety and Performance Requirements is clear. AMRA consistently demonstrates robust scientific methods and maturity in product development as they continue to take key steps in clinically translating their exciting MRI-based technologies.
AMRA® Profiler 4 provides clinicians with fat distribution, e.g., liver fat, and muscle composition biomarkers that comprise a detailed body composition profile to assist in diagnosis. Implemented right at the clinic, AMRA® Profiler 4 provides rapid and precise body composition measurements in relation to normative data, contextualizing insights at the individual patient level, with high accuracy. The AMRA biomarkers underlying this technology have proven to be useful in metabolic disease research efforts using the AMRA® Researcher service, and AMRA® Profiler 4’s recent MDR certification brings these powerful and unique biomarkers one step closer to patients everywhere.
Currently, AMRA® Profiler 4 is fully available through AMRA’s service provision in the UK, US, and Canada - with plans to roll out the product in the EU in the future following this MDR certificate milestone. If you or your organization are based in the currently cleared markets and would like to know more about bringing AMRA® Profiler 4 to your clinic, please contact info@amramedical.com.
You can learn how AMRA is using MRI-based fat distribution and muscle composition assessments to advance both research and clinical care by visiting our website, or get in touch with our knowledgeable scientists at info@amramedical.com to learn more about what AMRA can do for your trials, or for your patients.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering services via their innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in fat distribution and muscle composition assessments in disease research and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829196647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phenom Named Strategic Leader in 2024 Fosway 9-Grid™ for Talent & People Success10.10.2024 11:30:00 CEST | Press release
Positioning Recognises Phenom’s Impact on Helping Europe’s Largest Companies Solve HR’s Biggest Talent Management Challenges Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010930504/en/ Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. (Graphic: Business Wire) Fosway Group identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sop
Thredd Reports Another Successful Quarter With Fintech Transaction Volumes up and New Issuer Signings10.10.2024 11:08:00 CEST | Press release
20% YOY organic transaction volume growth and new client signings in APAC and the U.S. 48% increase YOY in Buy Now Pay Later (BNPL) solutions across the UK, Europe, and APAC regions B2B virtual card payments up significantly with APAC clients leading the charge Thredd, a leading next-generation payments processor, today announced positive third-quarter results with 2024 on track to outperform all prior years, powered by transactions up 20%, key global client wins, programme expansions and growth in distinct payment segments and markets. According to the company, Thredd signed key new clients in the third quarter including digital banks and saw existing B2B programme expansion to the US. The company also announced the launch of virtual card programmes and a major card programme migration in APAC. The company said these wins and programme launches follow other partnership extensions earlier in the summer with segment leaders in Buy Now Pay Later (BNPL), B2B payments, disbursements, and s
Allianz Is the World’s #1 Insurance Brand, Ranking Among the Top 30 Global Brands for the First Time10.10.2024 11:03:00 CEST | Press release
Interbrand 2024 Best Global Brands ranking: Allianz jumps to 29th position and further maximises brand value to 23,5 billion USD.Strong employee value proposition: Allianz also climbed to 7th place in the Fortune 100 Best Companies to Work For® in Europe 2024 certification.The 2024 Olympic and Paralympic Games in Paris have been the biggest marketing asset to date for Allianz, uniting athletes from over 200 nations and billions of fans in peaceful competitions.Disaster relief efforts for flood events and sustainability commitments contribute to building trust in the Allianz brand. Allianz's steady rise to the top of the world's most powerful brands continued in 2024, driven by a strong employee value proposition, a commitment to building trust through sustainability and societal leadership as well as top-tier partnerships in sport. For the first time, Allianz has been named one of the 30 most valuable brands in the world, moving up two places to the 29th position in this year’s Best Gl
MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research10.10.2024 09:01:00 CEST | Press release
The San Francisco-based company with an R&D facility in Bilbao has also unveiled its Platforma.bio Software Development Kit, transforming how biologists analyze genomic data to drive drug discovery and advance adjacent fields in medicine. This latest financing bolsters the company's efforts to transform computational biology on a global scale and empower researchers with innovative tools to accelerate discoveries and advancements in the field Led by Kfund with participation from Speedinvest, Acrobator Ventures, Ten13, Somersault Ventures, EGB Capital, and Courtyard Ventures Series A capital to be utilized for attracting top-tier talent and expanding into new markets, with a strategic emphasis on the United States MiLaboratories, a leader in computational biology innovation, is thrilled to announce the successful close of its Series A funding round, led by Madrid-based Kfund, with additional backing from Speedinvest and other prominent international investors. This funding milestone com
Delinea Recognized as a Leader in the KuppingerCole Leadership Compass™ for Privileged Access Management (PAM) 202410.10.2024 09:00:00 CEST | Press release
Delinea’s Continued Innovation and Comprehensive Approach to Identity Security Highlighted in Leading Analyst Report Delinea, a pioneering provider of solutions for securing identities through centralized authorization, today announced its recognition as a Leader in the KuppingerCole Leadership Compass for Privileged Access Management (PAM), 2024. This marks another significant milestone for Delinea as it continues to lead the industry in providing secure and scalable PAM solutions that empower organizations to safeguard their most critical identities and assets. “We are honored to be recognized as a Leader in the 2024 KuppingerCole Leadership Compass for PAM,” said Art Gilliland, CEO of Delinea. “This achievement reflects our commitment to developing innovative solutions for the growing complexity of identity security. With our broad product portfolio and cloud-first approach, Delinea has established itself as a market leader known for ease of use. As human and machine identities incr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom